| D007533 |
Isoleucine-tRNA Ligase |
An enzyme that activates isoleucine with its specific transfer RNA. EC 6.1.1.5. |
Isoleucyl T RNA Synthetase,Isoleucyl- tRNA Synthetase ILS1,Isoleucyl-tRNA Synthetase 1,Isoleucyl-tRNA Synthetase ILES1,Ile-tRNA Ligase,Isoleucyl-tRNA Synthetase,1, Isoleucyl-tRNA Synthetase,ILES1, Isoleucyl-tRNA Synthetase,Ile tRNA Ligase,Isoleucine tRNA Ligase,Isoleucyl tRNA Synthetase,Isoleucyl tRNA Synthetase 1,Isoleucyl tRNA Synthetase ILES1,Isoleucyl tRNA Synthetase ILS1,Ligase, Ile-tRNA,Ligase, Isoleucine-tRNA,Synthetase 1, Isoleucyl-tRNA,Synthetase ILES1, Isoleucyl-tRNA,Synthetase, Isoleucyl-tRNA |
|
| D008297 |
Male |
|
Males |
|
| D003882 |
Dermatomyositis |
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) |
Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis |
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000368 |
Aged |
A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. |
Elderly |
|
| D001323 |
Autoantibodies |
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. |
Autoantibody |
|
| D017285 |
Polymyositis |
Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9) |
Myositis, Multiple,Polymyositis Ossificans,Polymyositis, Idiopathic,Idiopathic Polymyositides,Idiopathic Polymyositis,Multiple Myositis,Myositides, Multiple,Ossificans, Polymyositis,Polymyositides,Polymyositides, Idiopathic |
|
| D017563 |
Lung Diseases, Interstitial |
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. |
Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial |
|